Current uses and future hopes for clinical pharmacology in the management of H1V infection

HIV Medicine

Volumn 1, Issue SUPPL. 2, 2000, Pages 12-17

  Back, D J ^a   Khoo, S H ^a   Maher B ^a   Gibbons, S E ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33747024572     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1293.2000.00001.x     Document Type: Article

References (24)

1. Ledergerber B, Egger M, Opravil M, eraJ. Clinical progression and virological failure on highly active anti-retroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999; 353: 863-868.
2. Barry MG, Mulcahy F, Merry C, Gibbons S, Back DJ. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pliarmacokinet 1999; 36: 289-304.
3. Flexner C. Drug interactions. In: Medscape HIV/AIDS Annual Update. Available at , 1999.
4. Hoetelmans RMW, Reijers MHE, Weverling GJ, et al. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy. AIDS 1998; 12: F111-F115.
5. Gieschke R, Fotteler B, Buss N, Steiner J-L. Relationship between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients. Clin Pliarmacokinet 1999; 37: 75-86.
6. Murphy RL, Sommadossi JP, Lamson M, étal. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1. J Infect Dis 1999; 179: 1116-1123.
7. Markowitz M, Saag M, Powderly WG, eraJ. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995;333: 1534-1539.
8. Emini EA. Resistance to anti-human immunodeficiency virus therapeutic agents. Adv £rp Med Biol 1995; 390: 187-195.
9. Stein DS, Fish DG, Bilello JA, étal A 24-week open-label Phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS 1996; 10: 485-492.
10. Acosta EP, Henry K, Weller D, étal. Indinavir pharmacokinetics and relationships between exposure and antiviral effect. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 1997.
11. Burger DM, Hoetélmans RMW, Hugen PWH, et al. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1 infected patients on indinavir-containing triple therapy. Antiviral Ther 1998; 3: 215-220.
12. Burger DM, Hoetélmans RMW, Mulder JW, etal Low plasma levels of indinavir (IDV) are highly predictive of virological treatment failure in patients using IDV-containing triple therapy. 12th World AIDS Conference, Geneva, July 1998; abstract P042275.
13. Descamps D, Flandre P, Gavez V, etal. Mechanisms of virologie failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. JAMA 2000; 283: 205-211.
14. Garraffo R, Durant J, Clevenbergh P, etal. Independent benefit of sufficient drug levels and genotypic analysis in salvage therapy: pharmacological data from the Viradapt study. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 1999; abstract 1166.
15. Burger DM, Hoetélmans RMW, Hugen PWH, Van Heewijk RPG, Aamoutse RE, Veldkamp AI for the ATHENA Study Group. ATHENA, a randomised, controlled clinical trial to evaluate whether therapeutic drug monitoring (TDM) contributed to reduced HIV-related morbidity and mortality. 1st International Workshop on Clinical Pharmacology of HIV Therapy, Noordwijk, 2000; abstract 6.6.
16. Van Heeswijk RPG, Veldkamp AI, Hoetélmans RMW, et al. The steady-state plasma concentrations of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1 infected individuals. AIDS 1999; 13: F95-F99.
17. Saag MS, Kilby M, Ehrensing E, etal. Modulation of saquinavir steady state pharmacokinetics with 'baby' doses of ritonavir in healthy volunteers. 7th European Conference on Clinical Aspects and Treatment of HIV Infection, Lisbon, October 1999; abstract 829.
18. Havlir DV, Hellman NS, Petropoulos a, etal. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir containing regimens. JAMA 2000; 283: 229-234.
19. Profit L, Eagling VA, Back DJ. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS 1999; 13: 1623-1627.
20. Lee CGL, Gottesman MM, Cardarelli CO, etal. HIV-1 protease inhibitors are substrates for the MDR-1 multidrug transporter. Biochemistry 1998; 37: 3594-3601.
21. Kirn RB, Fromm MF, Wandel C, etal. The drug transporter Pglycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998; 101: 289-294.
22. Huisman MT, Smit JW, Schinkel AH. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 2000; 14: 237-242.
23. Gutmann H, Flicker G, Drewe J, Toeroek M, Miller DS. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol 1999; 56: 383-389.
24. Back D, Jones K, Mäher B, Hoggard P. Cellular influx/efflux of protease inhibitors in vitro. 7th Conference on Retroiïruses and Opportunistic Infections, San Francisco, February 2000; abstract 93.